FFR – Medxy AI

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study

By MedXY 05/09/2026

ORBITA-FIRE study reveals personalized physiological thresholds for angina that are lower than current diagnostic standards. These thresholds vary during exercise and predict PCI treatment success, challenging universal ischemia-based guidelines.

Cardiology news

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

By MedXY 02/04/2026

The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

By MedXY 02/04/2026

An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable win ratio of 1.25.

Cardiology news

FFR-Guided Revascularization Significantly Reduces 12-Month MACCE in TAVI Patients: The FAITAVI Trial

By MedXY 01/03/2026

The FAITAVI trial demonstrates that physiology-guided PCI using FFR significantly reduces major adverse cardiac events, particularly mortality, compared to angiography-guided PCI in elderly patients undergoing TAVI with intermediate coronary lesions.

Cardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

By MedXY 08/16/2025

This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.